William McKee Net Worth

The estimated Net Worth of William Mckee is at least $809 Tysiąc dollars as of 10 May 2023. Mr. Mckee owns over 22,000 units of Aileron Therapeutics Inc stock worth over $687,686 and over the last 9 years he sold ALRN stock worth over $121,537. In addition, he makes $0 as Independent Director at Aileron Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McKee ALRN stock SEC Form 4 insiders trading

William has made over 3 trades of the Aileron Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 22,000 units of ALRN stock worth $69,080 on 10 May 2023.

The largest trade he's ever made was selling 22,322 units of Aileron Therapeutics Inc stock on 12 May 2022 worth over $52,457. On average, William trades about 2,361 units every 45 days since 2015. As of 10 May 2023 he still owns at least 238,780 units of Aileron Therapeutics Inc stock.

You can see the complete history of Mr. Mckee stock trades at the bottom of the page.

William McKee biography

William T. McKee CPA serves as Independent Director of the Company. Mr. McKee has served as the Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving the pharmaceutical and biotechnology industry, since June 2010. Mr. McKee served as chief operating officer and chief financial officer for EKR Therapeutics, Inc. from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. From December 2008 until March 2010, Mr. McKee served as the executive vice president, chief financial officer and treasurer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited and the successor entity to Barr Pharmaceuticals, Inc., which was acquired by Teva in December 2008. Mr. McKee was also executive vice president and chief financial officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr from 1995 until its acquisition. Prior to joining Barr, Mr. McKee served as director of international operations and vice president-finance at Absolute Entertainment, Inc. from June 1993 until December 1994. From 1990 until June 1993, Mr. McKee worked at Gramkow & Carnevale, CPA’s, and from 1983 until 1990, he worked at Deloitte & Touche LLP. Mr. McKee serves as a member of the board of directors and chairman of the audit committee of Assertio Therapeutics, Inc., a specialty pharmaceutical company, and Agile Therapeutics, Inc., a biopharmaceutical company. Mr. McKee received a B.B.A. from the University of Notre Dame.

How old is William McKee?

William McKee is 58, he's been the Independent Director of Aileron Therapeutics Inc since 2019. There are 3 older and 9 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.

What's William McKee's mailing address?

William's mailing address filed with the SEC is ASSERTIO HOLDINGS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST, IL, 60045.

Insiders trading at Aileron Therapeutics Inc

Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag... oraz Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.

What does Aileron Therapeutics Inc do?

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig

Complete history of Mr. Mckee stock trades at Agile Therapeutics Inc, Aileron Therapeutics Inc, Assertio oraz C4 Therapeutics

Aileron Therapeutics Inc executives and stock owners

Aileron Therapeutics Inc executives and other stock owners filed with the SEC include:

• Manuel Aivado,
  President, Chief Executive Officer, Director
• Dr. Manuel C. Aivado,
  Pres, CEO & Director
• Dr. Vojislav Vukovic M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Vojislav Vukovic,
  Senior Vice President, Chief Medical Officer
• Richard J. Wanstall M.B.A.,
  SVP, CFO & Treasurer
• D. Allen Annis,
  Senior Vice President - Research
• Jeffrey Bailey,
  Chairman of the Board
• Rick Wanstall,
  Chief Financial Officer, Treasurer
• Jodie Morrison,
  Independent Director
• Reinhard Ambros,
  Lead Independent Director
• Josef von Rickenbach,
  Independent Director
• Nolan Sigal,
  Independent Director
• William McKee,
  Independent Director
• Dr. D. Allen Annis Ph.D.,
  Sr. VP of Research
• Alan A Musso,
  
• Allen Annis,
  SVP, Research
• 2008 Trust The Edward & Mic...,
  10% owner
• Edward M Elkin,
  Director
• Gary J Knauer,
  CFO, Treasurer & Secretary
• Glenda Baskin Glover,
  Director
• Joseph Looney,
  Director
• Peter Gutmann,
  Director
• Gary Gelman,
  Chairman, President & CEO
• Kira Nelson,
  See Remarks
• Donald Dougherty,
  SVP & Chief Financial Officer
• Caleb Maxfield Winder,
  Director
• Tree Partners Ii Annex, L...,
  10% owner
• Ib Investment Co., Ltd. Aju,
  10% owner
• Medical Fund Lp Gullans Ste...,
  
• Ltd. Kck,
  10% owner
• Llc Cvf,,
  10% owner
• John H Mcarthur,
  Director
• Joseph A., Iii Yanchik,
  See Remarks
• Armen Shanafelt,
  Director
• Brian M. Jr. Gallagher,
  Director
• Tree Partners Ii Lp Apple,
  10% owner
• Management Group, Llc Lilly...,
  
• Emerging Markets Ltd. Sigma,
  10% owner
• Jon B. Platt,
  10% owner
• Scott Kapnick,
  Director
• Bioventures Ltd Novartis Ag...,
  
• Kathryn Gregory,
  SVP, Chief Business Officer
• John P Phd Longenecker,
  President and CEO
• Muneer A Satter,
  See Remarks
• Vojo Vukovic,
  Chief Medical Officer
• William Fairey,
  
• James Brian Windsor,
  President and COO
• Of Texas/Texas Am Investmen...,
  10% owner